US20070065370A1 - Suspension aerosol formulationis of pharmaceutical products - Google Patents

Suspension aerosol formulationis of pharmaceutical products Download PDF

Info

Publication number
US20070065370A1
US20070065370A1 US11/553,508 US55350806A US2007065370A1 US 20070065370 A1 US20070065370 A1 US 20070065370A1 US 55350806 A US55350806 A US 55350806A US 2007065370 A1 US2007065370 A1 US 2007065370A1
Authority
US
United States
Prior art keywords
specified
active substances
combination
propellent gases
propellent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/553,508
Inventor
Hans-Hermann Weil
Ottfried Daab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6399399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070065370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim GmbH
Priority to US11/553,508 priority Critical patent/US20070065370A1/en
Publication of US20070065370A1 publication Critical patent/US20070065370A1/en
Priority to US12/179,785 priority patent/US20090104127A1/en
Priority to US12/891,076 priority patent/US20110014134A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols

Definitions

  • the invention relates to new propellent gases which contain as a typical ingredient 1,1,1,2,3,3,3-heptafluoropropane (TG 227), the use of these propellent gases in pharmaceutical preparations suitable for producing aerosols, and these pharmaceutical preparations themselves.
  • TG 227 1,1,1,2,3,3,3-heptafluoropropane
  • Aerosols of powdered (micronised) drugs are used widely in therapy, e.g. in the treatment of obstructive diseases of the respiratory tract. If such aerosols are not produced by atomising the pharmaceutical powder or by spraying solutions, suspensions of the drugs in liquefied propellent gases are used.
  • the latter consist primarily of mixtures of TG 11 (trichlorofluoromethane), TG 12 (dichlorodifluoromethane) and TG 114 (1,2-dichloro-1,1,2,2-tetrafluoroethane), optionally with the addition of lower alkanes such as butane or pentane, or with the addition of DME (dimethylether). Mixtures of this kind are known for example from German Patent 1178975.
  • TG 227 (1,1,1,2,3,3,3-heptafluoropropane, optionally in admixture with one of more propellent gases from the group comprising T 11 (trichlorofluoromethane), TG 12 (dichlorodifluoro-methane), TG 114 (1,2-dichloro-1,1,2,2-tetrafluoroethane), propane, butane, pentane and DME (dimethylether) is particularly suitable for use in therapeutic preparations.
  • propellent gases from the group comprising T 11 (trichlorofluoromethane), TG 12 (dichlorodifluoro-methane), TG 114 (1,2-dichloro-1,1,2,2-tetrafluoroethane), propane, butane, pentane and DME (dimethylether) is particularly suitable for use in therapeutic preparations.
  • the compounds to be used in addition to TG 227 are added if the properties of the propellent gas are to be modified, e.g. if the liquefied propellent gas is to have a different density, different pressure or different solubility characteristics.
  • Pharmaceutical preparations based on the propellent gas contain an active substance in finely divided form, usually as a suspension, and generally also contain surface-active substances, e.g. a phospholipid (such as lecithin), an ester of a polyalcohol (such as sorbitol) with higher saturated or unsaturated fatty acids (e.g.
  • stearic, palmitic or oleic acid such as sorbitan trioleate, or a polyethoxysorbitan ester of a higher, preferably unsaturated fatty acid.
  • the adjuvant may be present in the mixture in dissolved or undissolved form.
  • the suspensions produced with the new propellent gas have a tendency to separate out. However, it has been found that the separated suspensions can easily be uniformly distributed again in the suspension medium simply by shaking.
  • the ratios of quantities of the individual ingredients of the propellent gas mixture may be varied within wide limits.
  • the proportion (in percent by weight) is 10 to 100% in the case of TG 227.
  • the mixture may also contain up to 50% propane and/or butane and/or pentane and/or DME and/or TG 11 and/or TG 12 and/or TG 114. Within the limits specified the ingredients are chosen to add up to 100%.
  • Propellent gas mixtures which contain 30 to 100% TG 227 are preferred.
  • the proportion of suspended drug in the finished preparation is between 0.001 and 5%, preferably between 0.005 and 3%, more particularly between 0.01 and 2%.
  • the surface-active substances are added in amounts of from 0.01 to 10%, preferably 0.05 to 5%, more particularly 0.1 to 3% (here, as in the case of the pharmaceutical substances, the percentage by weight of the finished preparation is given).
  • the pharmaceutical substances used in the new preparations may be any of the substances suitable for use by inhalation or possibly for intranasal administration. They include, therefore, in particular betanimetics, anticholinergics, steroids, antiallergics, PAF-antagonists and combinations of these active substances.
  • the active substances may also be combined, e.g. betamimetics plus anticholinergics or betamimetics plus antiallergics.

Abstract

Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.

Description

  • The invention relates to new propellent gases which contain as a typical ingredient 1,1,1,2,3,3,3-heptafluoropropane (TG 227), the use of these propellent gases in pharmaceutical preparations suitable for producing aerosols, and these pharmaceutical preparations themselves.
  • Aerosols of powdered (micronised) drugs are used widely in therapy, e.g. in the treatment of obstructive diseases of the respiratory tract. If such aerosols are not produced by atomising the pharmaceutical powder or by spraying solutions, suspensions of the drugs in liquefied propellent gases are used. The latter consist primarily of mixtures of TG 11 (trichlorofluoromethane), TG 12 (dichlorodifluoromethane) and TG 114 (1,2-dichloro-1,1,2,2-tetrafluoroethane), optionally with the addition of lower alkanes such as butane or pentane, or with the addition of DME (dimethylether). Mixtures of this kind are known for example from German Patent 1178975.
  • Owing to their harmful effect on the earth's atmosphere (destruction of the ozone layer, Greenhouse effect) the use of chlorofluorocarbons has become a problem, with the result that the search is on for other propellent gases or propellent gas mixtures which do not have the above-mentioned harmful effects or, at least, have them to a lesser degree.
  • However, this search has come up against major problems, since propellent gases for therapeutic use have to satisfy numerous criteria which cannot easily be reconciled, e.g. in terms of toxicity, stability, vapour pressure, density and solubility characteristics.
  • As has now been found, TG 227 (1,1,1,2,3,3,3-heptafluoropropane, optionally in admixture with one of more propellent gases from the group comprising T 11 (trichlorofluoromethane), TG 12 (dichlorodifluoro-methane), TG 114 (1,2-dichloro-1,1,2,2-tetrafluoroethane), propane, butane, pentane and DME (dimethylether) is particularly suitable for use in therapeutic preparations.
  • The compounds to be used in addition to TG 227 are added if the properties of the propellent gas are to be modified, e.g. if the liquefied propellent gas is to have a different density, different pressure or different solubility characteristics. Pharmaceutical preparations based on the propellent gas contain an active substance in finely divided form, usually as a suspension, and generally also contain surface-active substances, e.g. a phospholipid (such as lecithin), an ester of a polyalcohol (such as sorbitol) with higher saturated or unsaturated fatty acids (e.g. stearic, palmitic or oleic acid), such as sorbitan trioleate, or a polyethoxysorbitan ester of a higher, preferably unsaturated fatty acid. The adjuvant may be present in the mixture in dissolved or undissolved form. In some cases, the suspensions produced with the new propellent gas have a tendency to separate out. However, it has been found that the separated suspensions can easily be uniformly distributed again in the suspension medium simply by shaking.
  • The ratios of quantities of the individual ingredients of the propellent gas mixture may be varied within wide limits. The proportion (in percent by weight) is 10 to 100% in the case of TG 227. The mixture may also contain up to 50% propane and/or butane and/or pentane and/or DME and/or TG 11 and/or TG 12 and/or TG 114. Within the limits specified the ingredients are chosen to add up to 100%. Propellent gas mixtures which contain 30 to 100% TG 227 are preferred.
  • The proportion of suspended drug in the finished preparation is between 0.001 and 5%, preferably between 0.005 and 3%, more particularly between 0.01 and 2%. The surface-active substances are added in amounts of from 0.01 to 10%, preferably 0.05 to 5%, more particularly 0.1 to 3% (here, as in the case of the pharmaceutical substances, the percentage by weight of the finished preparation is given). The pharmaceutical substances used in the new preparations may be any of the substances suitable for use by inhalation or possibly for intranasal administration. They include, therefore, in particular betanimetics, anticholinergics, steroids, antiallergics, PAF-antagonists and combinations of these active substances.
  • The following are given as specific examples:
  • Examples of Betamimetics:
    • Bambuterol
    • Bitolterol
    • Carbuterol
    • Clenbuterol
    • Fenoterol
    • Hexoprenalin
    • Ibuterol
    • Pirbuterol
    • Procaterol
    • Reproterol
    • Salbutamol
    • Salmeterol
    • Sultonterol
    • Terbutalin
    • Tulobuterol
    • 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol
    • erythro-5′-hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one
    • 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol
    • 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol.
      Examples of anticholinergics:
    • Ipratropium bromide
    • Oxitropium bromide
    • Trospium chloride
    • Benzilic acid-N-β-fluoroethylnortropine ester
    • methobromide
      Examples of steroids:
    • Budesonide
    • Beclomethasone (or the 17, 21-dipropionate thereof)
    • Dexamethason-21-isonicotinate
    • Flunisolide
      Examples of Antiallergics:
    • Disodium cromoglycate
    • Nedocromil
      Examples of PAF-Antagonists:
    • WEB 2086
    • WEB 2170
    • WEB 2347
  • The active substances may also be combined, e.g. betamimetics plus anticholinergics or betamimetics plus antiallergics.
  • Examples of preparations according to the invention (amounts given in percent by weight):
    1) 0.10% Oxitropium bromide 2) 0.3% Fenoterol
    0.01% Soya lecithin 0.1% Soya lecithin
    4.0% Pentane 10.0% Pentane
    95.89% TG 227 70.0% TG 227
    19.6% TG 134a
    3) 0.1% Ipratropium bromide 4) 0.3% Fenoterol
    0.1% Soya lecithin 0.1% Soya lecithin
    20.0% Pentane 30.0% TG 11
    20.0% Butane 69.6% TG 227
    49.8% TG 11
    5) 1.5% Disodium 6) 0.3% Salbutamol
    cromoglicate 0.2% Span 85
    0.1% Tween 20 20.0% Pentane
    98.4% TG 227 60.0% TG 227
    1.4% Butane 19.5% TG 12
    7) 0.15% Fenoterol 8) 0.1% Ipratropium-
    0.06% Ipratropium- bromide
    bromide 0.1% Soya lecithin
    0.10% Soya lecithin 15.3% Propane
    40.00% TG 11 30.5% TG 11
    19.69% Propane 54.0% TG 227
    40.00% TG 227

Claims (11)

1. Propellent gases characterised in that they contain TG 227, optionally in admixture with one of more propellent gases from the group comprising TG 11, TG 12, TG 114, propane, butane, pentane and DME.
2. Propellent gases according to claim 1, characterised in that they additionally contain at least one surface-active substance.
3. Propellent gases according to claim 2, characterised in that the surface-active substance is a phospholipid, a sorbitan ester with a higher saturated or unsaturated fatty acid or a polyethoxysorbitan ester of a higher, preferably unsaturated fatty acid.
4. Propellent gases according to claim 2, characterised in that the surface-active substance is a lecithin, a polyethoxyethylenesorbitan oleate or sorbitan trioleate.
5. Pharmaceutical preparations for producing powder aerosols based on propellent gases according to claim 1, 2, 3 or 4, characterised in that they contain as active substance a betamimetic, an anticholinergic, a steroid, an antiallergic or a PAF-antagonist or a combination of such compounds.
6. Pharmaceutical preparations according to claim 5, characterised in that the betamimetic used is:
Bambuterol
Bitolterol
Carbuterol
Clenbuterol
Fenoterol
Hexoprenalin
Ibuterol
Pirbuterol
Procaterol
Reproterol
Salbutamol
Salmeterol
Sulfonterol
Terbutalin
Tulobuterol
1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol
erythro-5′-hydroxy-8′-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one
1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol
1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol
the anticholinergic used is:
Ipratropium bromide
Oxitropium bromide
Trospium chloride
Benzilic acid-N-β-fluoroethylnortropine ester
methobromide
the steroid used is:
Budesonide
Beclomethasone (or the 17, 21-dipropionate thereof)
Dexamethason-21-isonicotinate
Flunisolide
The antiallergic agent is:
Disodium cromoglycate
Nedocromil
The PAF-antagonist is:
WEB 2086
WEB 2170
WEB 2347.
7. Pharmaceutical preparations according to claim 5, characterised in that the combination of the active substances comprises one of the betamimetics specified in claim 6 and one of the anticholinergics specified in claim 6.
8. Pharmaceutical preparation according to claim 5, characterised in that the combination of the active substances comprises one of the betamimetics specified in claim 6 and disodium chromoglycate.
9. Pharmaceutical preparation according to claim 5, characterised in that the combination of the active substances contains one of the betamimetics specified in claim 6 and one of the PAF-antagonists specified in claim 6.
10. Pharmaceutical preparation according to claim 5, characterised in that the combination of the active substances comprises disodium chromoglycate and one of the PAF-antagonists specified in claim 6.
11. Process for preparing pharmaceutical preparations according to claims 5 to 10, characterised in that pharmaceutically active substances micronised by conventional methods are suspended in a liquefied propellent gas mixture according to claim 1, 2, 3 or 4, optionally with the addition of surface-active substances.
US11/553,508 1990-02-03 2006-10-27 Suspension aerosol formulationis of pharmaceutical products Abandoned US20070065370A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/553,508 US20070065370A1 (en) 1990-02-03 2006-10-27 Suspension aerosol formulationis of pharmaceutical products
US12/179,785 US20090104127A1 (en) 1990-02-03 2008-07-25 Suspension aerosol formulations of pharmaceutical products
US12/891,076 US20110014134A1 (en) 1990-02-03 2010-09-27 Suspension aerosol formulations of pharmaceutical products

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
DEP4003270.1 1990-02-03
DE4003270A DE4003270A1 (en) 1990-02-03 1990-02-03 NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
WOPCT/EP91/00178 1991-01-31
PCT/EP1991/000178 WO1991011496A1 (en) 1990-02-03 1991-01-31 Novel vehicle gases and their use in medical preparations
US91035392A 1992-10-01 1992-10-01
US28240294A 1994-07-28 1994-07-28
US59723096A 1996-02-06 1996-02-06
US99025297A 1997-12-15 1997-12-15
US09/525,431 US6419899B1 (en) 1990-01-31 2000-03-14 Suspension aerosol formulations of pharmaceutical products
US10/072,400 US20020071812A1 (en) 1990-01-31 2002-02-06 Propellent gases and their use in pharmaceutical preparations
US10/638,987 US20040028618A1 (en) 1990-02-03 2003-08-12 Suspension aerosol formulations of pharmaceutical products
US10/934,611 US7160538B2 (en) 1990-02-03 2004-09-03 Suspension aerosol formulations of pharmaceutical products
US11/553,508 US20070065370A1 (en) 1990-02-03 2006-10-27 Suspension aerosol formulationis of pharmaceutical products

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/934,611 Continuation US7160538B2 (en) 1990-02-03 2004-09-03 Suspension aerosol formulations of pharmaceutical products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/179,785 Continuation US20090104127A1 (en) 1990-02-03 2008-07-25 Suspension aerosol formulations of pharmaceutical products

Publications (1)

Publication Number Publication Date
US20070065370A1 true US20070065370A1 (en) 2007-03-22

Family

ID=6399399

Family Applications (7)

Application Number Title Priority Date Filing Date
US09/525,431 Expired - Fee Related US6419899B1 (en) 1990-01-31 2000-03-14 Suspension aerosol formulations of pharmaceutical products
US10/072,400 Abandoned US20020071812A1 (en) 1990-01-31 2002-02-06 Propellent gases and their use in pharmaceutical preparations
US10/638,987 Abandoned US20040028618A1 (en) 1990-02-03 2003-08-12 Suspension aerosol formulations of pharmaceutical products
US10/934,611 Expired - Lifetime US7160538B2 (en) 1990-02-03 2004-09-03 Suspension aerosol formulations of pharmaceutical products
US11/553,508 Abandoned US20070065370A1 (en) 1990-02-03 2006-10-27 Suspension aerosol formulationis of pharmaceutical products
US12/179,785 Abandoned US20090104127A1 (en) 1990-02-03 2008-07-25 Suspension aerosol formulations of pharmaceutical products
US12/891,076 Abandoned US20110014134A1 (en) 1990-02-03 2010-09-27 Suspension aerosol formulations of pharmaceutical products

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US09/525,431 Expired - Fee Related US6419899B1 (en) 1990-01-31 2000-03-14 Suspension aerosol formulations of pharmaceutical products
US10/072,400 Abandoned US20020071812A1 (en) 1990-01-31 2002-02-06 Propellent gases and their use in pharmaceutical preparations
US10/638,987 Abandoned US20040028618A1 (en) 1990-02-03 2003-08-12 Suspension aerosol formulations of pharmaceutical products
US10/934,611 Expired - Lifetime US7160538B2 (en) 1990-02-03 2004-09-03 Suspension aerosol formulations of pharmaceutical products

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/179,785 Abandoned US20090104127A1 (en) 1990-02-03 2008-07-25 Suspension aerosol formulations of pharmaceutical products
US12/891,076 Abandoned US20110014134A1 (en) 1990-02-03 2010-09-27 Suspension aerosol formulations of pharmaceutical products

Country Status (26)

Country Link
US (7) US6419899B1 (en)
EP (1) EP0513099B1 (en)
JP (1) JP3497162B2 (en)
KR (1) KR920703034A (en)
AT (1) ATE185587T1 (en)
AU (1) AU656129B2 (en)
CA (1) CA2075060C (en)
CZ (1) CZ285209B6 (en)
DE (2) DE4003270A1 (en)
DK (1) DK0513099T3 (en)
ES (1) ES2139574T3 (en)
FI (1) FI103348B1 (en)
GR (1) GR3032176T3 (en)
HK (1) HK1010737A1 (en)
HR (1) HRP940737B1 (en)
HU (1) HU218664B (en)
IL (1) IL97024A0 (en)
NO (1) NO302420B1 (en)
NZ (1) NZ236974A (en)
PT (1) PT96635B (en)
RU (1) RU2118170C1 (en)
SI (1) SI9110155B (en)
SK (1) SK281440B6 (en)
WO (1) WO1991011496A1 (en)
YU (1) YU48509B (en)
ZA (1) ZA91756B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003270A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
MX9203481A (en) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg FORMULATIONS.
DE69105212T2 (en) * 1990-10-18 1995-03-23 Minnesota Mining & Mfg AEROSOL PREPARATION CONTAINING BECLOMETASON 17.21 DIPROPIONATE.
DK0656207T4 (en) † 1991-06-10 2009-11-30 Schering Corp Aerosol formulations without chlorofluorocarbon compounds
US5221492A (en) * 1991-08-23 1993-06-22 E. I. Du Pont De Nemours And Company Azeotropic mixture of perfluoropropane and dimethyl ether
GB9118830D0 (en) * 1991-09-03 1991-10-16 Minnesota Mining & Mfg Medical aerosol formulations
WO1993011744A1 (en) 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ES2216800T3 (en) * 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company AEROSOL FORMULATIONS IN SUSPENSION.
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
WO1993019117A1 (en) * 1992-03-26 1993-09-30 Great Lakes Chemical Corporation Azeotrope-like compositions of 1,1,1,2,3,3,3-heptafluoropropane and 1,1-difluoroethane
RO117414B1 (en) * 1992-12-09 2002-03-29 Jager Paul D Waterbury Pharmaceutical composition of gas dispersoid in solution
CA2178473C (en) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
PL320856A1 (en) 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
US6135628A (en) * 1995-10-13 2000-10-24 Boehringer Ingelheim Pharmceuticals, Inc. Method and apparatus for homogenizing aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
DE19652790A1 (en) * 1996-12-18 1998-06-25 Hermes Fabrik Pharm Praeparate Pharmaceutical preparations
US6235265B1 (en) * 1998-10-28 2001-05-22 Alliedsignal Inc. Evaporative coolant for topical anesthesia comprising hydrofluorocarbons and/or hydrochlorofluorocarbons
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
DE10050994A1 (en) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease
DE10062712A1 (en) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and corticosteroids
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US7273603B2 (en) 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
US20050136009A1 (en) * 2003-10-20 2005-06-23 Schering Corporation Pharmaceutical compositions
CA2571519C (en) * 2004-07-02 2013-05-14 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
WO2006114379A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
DE102006017320A1 (en) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
CN104188907A (en) 2007-02-11 2014-12-10 Map药物公司 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
EP2282418A3 (en) 2009-06-23 2011-03-09 Alcatel Lucent A station comprising at least two transmit antennas, and a method of transmitting therefrom
US9394314B2 (en) 2012-12-21 2016-07-19 Map Pharmaceuticals, Inc. 8′-hydroxy-dihydroergotamine compounds and compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US6419899B1 (en) * 1990-01-31 2002-07-16 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490764A (en) * 1945-07-04 1949-12-13 Kinetic Chemicals Inc Fluorinated organic compounds
BE556587A (en) 1957-01-31 1957-04-11
GB902590A (en) 1960-03-22 1962-08-01 Allied Chem Production of heptafluoropropane
US3095355A (en) * 1961-10-12 1963-06-25 Revlon Aerosol composition
NL289785A (en) * 1962-11-29
DE1542076A1 (en) * 1966-04-21 1970-03-26 Colgate Palmolive Co Aerosol propellant
US3369913A (en) * 1967-03-20 1968-02-20 Union Carbide Corp Self-propelling food mixture
DE1719443B2 (en) 1967-10-07 1973-04-05 SUSPENSION AEROSOLS AND THE PROCESS FOR THEIR PRODUCTION
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
IL51314A (en) 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
NL7708731A (en) * 1976-08-13 1978-02-15 Montedison Spa PROCESS FOR THE PREPARATION OF NEW DRIVER COMPOSITIONS FOR AEROSOLS.
US4174795A (en) * 1977-02-14 1979-11-20 Bohm Leslie E Pannier mounting arrangement for cycles
GB2001334B (en) 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
CA1136547A (en) 1979-03-08 1982-11-30 Song-Ling Lin Aerosol anesthetic compositions
JPS55131096A (en) 1979-03-30 1980-10-11 Daikin Ind Ltd Working fluid for rankine cycle
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
AU7288081A (en) * 1980-07-16 1982-01-21 Glaxo Group Limited 11alpha-amino-androstanes
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US4778674A (en) * 1986-05-28 1988-10-18 Richardson-Vicks Inc. Dry aerosol foam
DE3735467A1 (en) 1987-10-20 1989-05-03 Bayer Ag METHOD FOR PRODUCING FLUORINATED C (DOWN ARROW) 4 (DOWN ARROW) - TO C (DOWN ARROW) 6 (DOWN ARROW) HYDROCARBONS AND NEW CYCLIC FLUORED HYDROGENED FUEL SOURCES (4) - UP TO C (DOWN ARROW) 6 (DOWN ARROW) HYDROCARBONS AS A FLUID GAS AND WORKING LIQUID FOR HEAT PUMP SYSTEMS
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DE3903336A1 (en) 1989-02-04 1990-08-09 Bayer Ag USING C (ARROW DOWN) 3 (DOWN ARROW) - UP TO C (DOWN ARROW) 5 (DOWN ARROW) -POLYFLUOROUS CANS AS PRESSURE GASES
DE3905726A1 (en) * 1989-02-24 1990-08-30 Hoechst Ag COMPRESSED GAS PACKING AND DRIVING AGENT FOR AEROSOLS
JP2642738B2 (en) 1989-04-13 1997-08-20 ライオン株式会社 Aerosol products for human body application
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Aerosol propellant compositions
DE4003272A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0653205B1 (en) 1991-06-10 2002-10-16 Schering Corporation Non-chloroflurocarbon aerosol formulations
DK0656207T4 (en) 1991-06-10 2009-11-30 Schering Corp Aerosol formulations without chlorofluorocarbon compounds
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
EP0550031B1 (en) 1991-12-31 1996-05-08 Hoechst Aktiengesellschaft Aerosol compositions
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
PL320856A1 (en) 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
CA2218179A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for beclomethasone dipropionate
CA2280099C (en) 1997-02-05 2005-12-27 Jago Pharma Ag Medical aerosol formulations
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US6419899B1 (en) * 1990-01-31 2002-07-16 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US7160538B2 (en) * 1990-02-03 2007-01-09 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products

Also Published As

Publication number Publication date
US20020071812A1 (en) 2002-06-13
US7160538B2 (en) 2007-01-09
GR3032176T3 (en) 2000-04-27
KR920703034A (en) 1992-12-17
SI9110155A (en) 1998-04-30
US20050031548A1 (en) 2005-02-10
FI923491A (en) 1992-08-03
NO923040L (en) 1992-07-31
PT96635A (en) 1991-10-31
FI103348B (en) 1999-06-15
RU2118170C1 (en) 1998-08-27
ZA91756B (en) 1992-10-28
FI103348B1 (en) 1999-06-15
JP3497162B2 (en) 2004-02-16
HUT62455A (en) 1993-05-28
CS9100265A2 (en) 1991-09-15
ATE185587T1 (en) 1999-10-15
HK1010737A1 (en) 1999-06-25
IL97024A0 (en) 1992-03-29
ES2139574T3 (en) 2000-02-16
HRP940737B1 (en) 2000-10-31
YU15591A (en) 1994-01-20
CA2075060A1 (en) 1991-08-04
NO923040D0 (en) 1992-07-31
SK281440B6 (en) 2001-03-12
DK0513099T3 (en) 2000-04-10
PT96635B (en) 1998-07-31
DE4003270A1 (en) 1991-08-08
HU9202508D0 (en) 1992-10-28
FI923491A0 (en) 1992-08-03
AU656129B2 (en) 1995-01-27
US20090104127A1 (en) 2009-04-23
CZ285209B6 (en) 1999-06-16
HU218664B (en) 2000-10-28
CA2075060C (en) 2001-01-02
AU7211691A (en) 1991-08-21
JPH05504350A (en) 1993-07-08
NO302420B1 (en) 1998-03-02
US6419899B1 (en) 2002-07-16
SI9110155B (en) 1999-06-30
DE59109161D1 (en) 1999-11-18
US20040028618A1 (en) 2004-02-12
HRP940737A2 (en) 1997-06-30
NZ236974A (en) 1993-07-27
YU48509B (en) 1998-09-18
EP0513099B1 (en) 1999-10-13
WO1991011496A1 (en) 1991-08-08
EP0513099A1 (en) 1992-11-19
US20110014134A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
US20070065370A1 (en) Suspension aerosol formulationis of pharmaceutical products
US6413497B1 (en) Pharmaceutical composition using a mixture of propellant gases for a metered dose inhaler
KR920703035A (en) Injection gas mixtures and their use in pharmaceutical formulations

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION